Skip to main content
Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Factors associated with Alzheimer’s disease prevalence and mortality in Brazil—An ecological study

  • Murilo Bastos ,

    Roles Conceptualization, Data curation, Investigation, Methodology, Writing – original draft

    Affiliations Laboratório de Neurociência e Comportamento, Universidade Estadual do Centro-Oeste, Guarapuava, PR, Brazil, Cline Research Center, Curitiba, PR, Brazil

  • Michael Pereira da Silva,

    Roles Conceptualization, Data curation, Methodology, Writing – original draft

    Affiliation Faculty of Medicine, Federal University of Rio Grande, Rio Grande, RS, Brazil

  • Danyele da Silva,

    Roles Methodology, Writing – original draft, Writing – review & editing

    Affiliation Departamento de Enfermagem, Universidade Estadual do Centro-Oeste, Guarapuava, PR, Brazil

  • Glauco Nonose Negrão,

    Roles Conceptualization, Methodology, Writing – review & editing

    Affiliation Associação de Estudos, Pesquisa e Assistência as Pessoas com Doença de Alzheimer, Universidade Estadual do Centro-Oeste, Guarapuava, PR, Brazil

  • Graziele Schumanski,

    Roles Conceptualization, Writing – review & editing

    Affiliation Profnit, Universidade Estadual do Centro-Oeste, Guarapuava, PR, Brazil

  • Weber Claudio Francisco Nunes da Silva,

    Roles Conceptualization, Supervision, Writing – review & editing

    Affiliation Associação de Estudos, Pesquisa e Assistência as Pessoas com Doença de Alzheimer, Universidade Estadual do Centro-Oeste, Guarapuava, PR, Brazil

  • Juliana Sartori Bonini

    Roles Conceptualization, Methodology, Supervision, Validation, Writing – review & editing

    Affiliations Laboratório de Neurociência e Comportamento, Universidade Estadual do Centro-Oeste, Guarapuava, PR, Brazil, Associação de Estudos, Pesquisa e Assistência as Pessoas com Doença de Alzheimer, Universidade Estadual do Centro-Oeste, Guarapuava, PR, Brazil


A few epidemiological studies are evaluating the prevalence and mortality rates of Alzheimer’s disease, with no one using a nationwide sample of Brazilian elderlies. This study aims to calculate the prevalence of Alzheimer’s disease and investigate possible associations with sociodemographic and lifestyle factors and the presence of diseases non-communicable, and the prevalence and mortality for all Brazilian state capitals. This is an ecological design study made with secondary public data provided by the Ministry of Health. Prevalence rates were calculated based on the analysis of the dispensing of Alzheimer’s disease-specific drugs. Correlation analyzes were performed between rates and factors, and a multiple linear regression analysis was used to analyze possible associations between variables, controlled for each other. AD prevalence was 313/100,000. Prevalence rates were positively associated with primary health care coverage factors and negatively associated with ultra-processed food consumption and physical activity levels. AD mortality was 98/100,000. Mortality rates were positively associated with the proportion of obese elderly and elderly living on up to half the minimum wage and were inversely associated with the proportion of elderly with diabetes factors. We found positive and negative associations of sociodemographic, behavioral and diabetes indicators with Alzheimer’s disease prevalence and mortality, which provide data that can be investigated by studies with different designs.


Aging causes a wide range of molecular and cellular damage which leads to a gradual decrease in physical and mental capacity, an increased risk of disease, and, ultimately, death [1]. It is estimated that by 2050, 21.4% of the world’s population will be over 60 years old [1]. The Brazilian Institute of Geography and Statistics estimates that in 2060, 25.5% of Brazilians will be over 65 years of age, and life expectancy might increase approximately 3 years (75.7 years in 2016 to 78.6 in 2030) [2].

Dementia syndromes are neurodegenerative diseases characterized by irreversible destruction of neurons resulting in a progressive and disabling loss of specific functions of the nervous system [3]. Alzheimer’s Disease (AD) is the primary and most prevalent dementia, accounting for about 60 to 70% of cases [4]. AD develops insidiously, continuously and slowly, having advanced age as its main risk factor [3]. AD is also related to other factors such as reduced brain cognitive reserve, reduced brain size, low educational level, low occupational complexity, low levels of physical activity throughout life [5, 6], and poor nutritional status [7].

However, even with the increase in the elderly population and, consequently, the possible increase in people with AD in Brazil, few epidemiological studies evaluated the AD prevalence and mortality rates using a nationwide sample of Brazilian elderlies. In fact, data regarding AD prevalence are restricted to specific states or cities [812] limiting the better understanding of how AD is prevalent and impact the mortality rates in elderly Brazilian. Furthermore, it also limits the knowledge of possible factors associated with the disease, such as sociodemographic, lifestyle, and the presence of other chronic diseases.

The Brazilian Unified Health System (UHS) offers specific drugs for AD treatment free of charge. Thus, AD prevalence might be estimated using data of the number of elderlies who took these drugs from UHS. Therefore, this study aims to verify the AD’s prevalence and mortality rates in all Brazilian state capitals. We also aimed to verify the association of sociodemographic, lifestyle, and other non-communicable diseases (NCDs) with AD prevalence and mortality.


Design and estimates of prevalence and mortality

It is an ecological epidemiological study based on secondary data from 2019 provided by the Brazilian Ministry of Health and the Health Indicators and Monitoring System for Elderly Policies (SISAP IDOSO) of the Oswaldo Cruz Foundation [13].

The Brazilian Unified Health System (UHS) offers specific drugs for AD treatment free of charge through the diagnosis of probable AD according to the Clinical Protocol and Therapeutic Guidelines [14]. This document establishes the criteria for the diagnosis and treatment and is essential for the dispensing of medication. We calculated the AD prevalence using the number of elderlies who took specific drugs to treat AD from the Brazilian UHS and the total elderly population of each state capital analyzed. The prevalence was expressed in cases for each 100,000 people (total number of patients/total population X 100,000 people). The data was obtained from the SISAP IDOSO database [13]. The AD’s mortality rate, expressed in deaths for each 100,000, was obtained from the Mortality Information System, accessed through the Ministry of Health database [15] (, filtering mortality by AD (ICD G30) for each state capital for people aged over 60 years.

Sociodemographic factors

The Human Development Index by cities (HDIm), Gini Index, per capita income, were obtained from the Brazilian Institute of Geography and Statistics [16] (IBGE) and corresponded to the most current data available since the last census was carried out in 2010.

The educational level was obtained from the VIGITEL Brazil survey in 2019 [17]. In addition, data on the percentage of elderly living on half (1/2) minimum wage and percentage of elderly living on a quarter (1/4) of the minimum wage were taken from SISAP IDOSO [13] and have 2010 as the year of reference.

Regarding the data on access to food, the Brazilian Scale of Food Insecurity was chosen, applied in the 2017–2018 Family Budget Survey, and made available by the IBGE portal [18], which ranks based on the score of nine questions about access to food and classifies the household in food security (FS) and food insecurity (FI), the latter still stratified into mild, moderate, and severe. However, in this study, we only used the FI data in the associations.

The data of primary health care coverage (PHC) were taken from the e-manager portal of the Ministry of Health [19] (, reference year was 2019, with PHC coverage defined as estimated population coverage in Primary Care, given by the percentage of the population covered by teams from the Family Health Strategy and by teams of equivalent traditional Primary Care, parameterized concerning the population estimate.

Lifestyle factors

The Physical Activity Level (PAL), considered as the percentage of elderly who practiced at least 150 minutes of moderate to vigorous physical activity (PA) per week; Ultra-processed foods consumption, considered as a percentage of the elderly population that consumes five or more servings of ultra-processed foods per day; Consumption of protective foods, considered as a percentage of the elderly population that consumes five or more minimally or unprocessed foods per day; Overweight, considered as a percentage of the elderly population with a body mass index (BMI) between 25 and 29.9 kg/m2; Obesity; considered as BMI ≥ 30kg/m2, were obtained from the VIGITEL 2019 survey [17].

Statistical analysis

The Shapiro-Wilk test verified data normality. Pearson’s correlation analyzed the association between mortality rates and obesity, physical activity level, hypertension, the proportion of elderly living on half the minimum wage, consumption of protective foods, food insecurity, HDIm, and Gini index. Spearman’s correlation test analyzed the association between the variables prevalence and women mortality rates, and the variables ultra-processed foods consumption, high educational level, and PHC.

Multiple linear regression analyzed the independent association of sociodemographic, lifestyle factors, and the presence of NCDs with AD prevalence and mortality rates. The variables of each model were included hierarchically and we dropped variables with p>0.20 using the backward procedure. The statistical significance level was set at p<0.05. All analyzes were performed using SPSS® version 24.0 statistical software.


The AD prevalence for all Brazilian capitals was 313/100,000 for overall, 340/100,000 among men and 240/100,000 among women. The city of Porto Alegre, Rio Grande do Sul showed the lowest AD prevalence for the overall (42/100,000) and each sex (Men: 33/100,000; Women: 47/100,000). Teresina (Piauí) showed the highest AD prevalence for the overall (902/100,000) and for each sex (Men: 747/100,000; Women: 1,000/100,000).

The AD mortality for all Brazilian capitals was 98/100,000 for overall, 73/100,000 among men and 108/100,000 among women. The city of Rio Branco (Acre) showed the lowest AD mortality for the overall analysis (27/100,000) and each sex (Men: 33/100,000; Women: 47/100,000). Vitória (Espírito Santo) showed the highest AD mortality for the overall (193/100,000) and each sex (Men: 163/100,000; Women: 244/100,000).

Table 1 shows the correlation between sociodemographic, lifestyle, and NCDs factors with the AD’s prevalence and mortality. We only found a significant correlation for mortality rates. The high educational level and HDI factors were positively correlated with AD mortality for the overall and each sex, with correlations ranging from r = 0.48 to 0.59. The proportion of elderly people living with up to half the minimum wage and food insecurity were inversely correlated with AD mortality for the overall and each sex (correlation ranging from r = -0.41 to -0.56).

Table 1. Correlation between prevalence and mortality of Alzheimer’s disease in 27 Brazilian capitals and sociodemographic, lifestyle, and non-communicable diseases (NCDs) factors.

A multiple linear regression analysis was used to verify factors independently associated with AD prevalence and mortality (Table 2). For AD prevalence, the regression analysis resulted in a statistically significant model (F(5,20) = 4,06 R2 = 0,50, R2 adjusted = 0,38, p = 0.01). The PHC coverage (B = 5.4, 95%CI = 1.15; 9.6, p = 0.01), consumption of ultra-processed foods (B = -41.8, 95%CI = -75.1; -8.5, p = 0.02) and physical activity level (B = -23.3, 95%CI = - 44.0; -2.6, p = 0.03) were significant predictors of AD prevalence.

Table 2. Multiple linear regression for factors associated with AD’s prevalence and mortality rates for Brazilian capitals (n = 27).

The regression analysis for AD mortality rate also resulted in a statistically significant model (F(3,22) = 7,25; R2 = 0,50; R2 adjusted = 0,49, p = 0.001). The proportion of elderly living with half the minimum wage (B = -3.2, 95%CI = -4.7; -1.7, p = 0.00), obesity (B = -4.1, 95%CI = -8.0; -0.3, p = 0.04) and diabetes prevalence (B = 4.9, 95%CI = 0.2; 9.6, p = 0.04) were predictors of AD mortality rates.


This study verified the prevalence and mortality rates of AD among elderly people of all Brazilian state capitals in 2019. In addition, the study found significant associations between prevalence rates with PHC coverage, ultra-processed foods consumption, and physical activity level, and between AD mortality rate and factors of the proportion of elderly who live on half the minimum wage, obesity, and diabetes.

Studies have shown variability in all type dementia’s prevalence, with an estimated worldwide prevalence of 800/100,000 in persons 55 to 65 years old; 2670/100,000 in 65 to 74 years old and 5140/100,000 in 70 to 79 years old, and AD’s prevalence of 3070/100,000 (3,1%) in persons with 60 to 69 years old; 108,800/100,000 (11%) in persons with 70 to 79 years old and 26150/100,000 (26%) in persons with age ≥ 90 years old [20]. However, we have dementia’s prevalence rates ranging from 4.66% in Europe to 8.48% in Latin America, and still with significant variability within continents, with 4.66% in southern Europe, up to 6.88% in the north, and in southern Latin America, ranging from 5.7% in Venezuela to 8.3% in Argentina [2126]. The AD’s prevalence found in this study was 313/100,000 (0.31%), lower than the rates found in other countries, especially of South American countries. However, considering the difficulty in systematizing information regarding new AD cases in Brazil, we assume that cases may be underreported, a situation that already occurs about dementia, both in high-income countries [27] and in low-income countries [28, 29] Another aspect that may be related to underreporting of AD is the low adherence to treatment with anticholinesterase inhibitors since its side effects can be hardly tolerated resulting in the treatment withdrawal [30].

AD’s mortality rates among all Brazilian capitals found in this study was 36 deaths per 100,000 elderlies. In 2019, dementia, including AD, was the 7th major cause of death worldwide [4] and, in Brazil, occupying 9th place in the ranking of elderly deaths in 2019 [15]. If we consider only high-income countries, AD mortality is the 2nd major cause of deaths [4]. Globally, AD and other dementias caused 1.9 million deaths in 2015 [31]. However, the true impact of dementia and AD on the mortality rates might be underestimated [32] since AD can make the elderly more vulnerable to other diseases that lead to death [33], in addition to the difficulty in determining the number of deaths caused by AD due to the way of recording the cause of death [34]. Therefore, even if AD does not occupy a high place in the ranking of causes of death in Brazilian elderlies, AD may be associated with other comorbidities that lead to elderly deaths, reinforcing the need of further investigation.

This study found that capitals with higher PHC coverage had higher AD prevalence. PHC is characterized by a set of individual and collective health actions, covering aspects of health promotion, disease prevention, diagnosis, treatment, rehabilitation, harm reduction, and health maintenance [35]. Elderlies with the subjective cognitive decline with a higher number of medical appointments had more frequent memory complaints than those with a lower number of appointments [36]. In Brazil, the elderly with AD visits a clinician more frequently compared to the elderly without AD, on the other hand, these individuals had fewer appointments with specialists [37]. Brazilian state capitals with higher PHC coverage might be more successful in screening AD cases because the healthcare system is more accessible to the community, especially those with lowest economic level.

PAL prevalence was inversely related to AD’s prevalence. For elderlies, the PA recommendation for substantial health benefits, including mental health, is 150–300 minutes of moderate-intensity, or 75–150 minutes of vigorous intensity, per week [38]. Physical inactivity presents a 12.7% population-attributable risk for AD worldwide and 21% for the US population [39]. In Brazil, the proportion of physically inactive elderly with AD was also higher compared to the elderly without AD [37]. Furthermore, a 20% reduction in the risk of developing dementia was attributed to engaging in any physical activity [36]. Therefore, our hypothesis was confirmed, that AD maybe was also influenced by the adequate PAL, engaging in PA practice can slow down cognitive decline in elderly people with high concentrations of tau protein in the brain compared to elderly people with low PAL [40].

A higher proportion of elderly who consume five or more servings of ultra-processed foods were inversely associated with the AD’s prevalence. The western standard of diet, composed of a good amount of processed foods with high levels of saturated fat and sugar, results in considerable adverse health effects [41], and these effects are not different to dementia and AD. Diets with high amounts of saturated fat and sugar worsened Aβ-42 concentrations in cerebrospinal fluid (FCS), which is an AD marker, compared to low amounts of fat and sugar diets [42]. Furthermore, dietary patterns such as the Mediterranean Diet, characterized by high consumption of fruits, vegetables, vegetables and cereals, olive oil, and moderate consumption of alcohol and red meat, are associated with lower rates of cognitive decline and significant reductions in AD rates [43]. However, we found an inverse association between consumption of ultra-processed foods and the prevalence of AD. As both variables refer to the same year, maybe the time of exposure to the risk factor consumption of ultra-processed food consumption has not yet been sufficient to cause an impact on the Alzheimer’s disease prevalence. Thus, further investigation should monitor the impact of ultra-processed food on the Alzheimer’s disease using a longitudinal design.

Our study showed that state capitals with higher diabetes prevalence had higher AD mortality rates. Type 2 Diabetes Mellitus (T2D) increases the risk of several types of dementia, including AD, through the formation of vascular lesions and ischemia, changing metabolic processes in the central nervous system, maintaining a chronic inflammatory process [44]. Furthermore, due to numerous similarities between diabetes and AD, some authors have called AD "Type 3 Diabetes" [45]. However, there seem to be no significant differences in in-hospital mortality between AD patients who had or did not have T2D, with only the risk ratio for the sum of comorbidities being significant [46]. Therefore, as the present study found that capitals with a higher prevalence of T2D have higher AD’s mortality and judging by the fewer studies specifically evaluating this association, further investigation should be carried out to better understand this relationship. However, regarding the difference between the result found in this study and the literature, one aspect of the potential for metabolic overlap of the two diseases, which makes any conclusions more difficult [47].

Finally, our study found a significant and negative association between the obesity prevalence and the AD’s mortality. Although the literature presents data related to a more accentuated cognitive impairment in obese individuals (BMI ≥30 kg/m2) [48, 49], the relationship with AD’s mortality presents results conflicting. For example, a greater body mass index can be protective against AD’s death and is inversely related to medial temporal atrophy [7]. On the other hand, lower BMI is associated with faster cognitive decline [50, 51]. These findings may seem somewhat contradictory, especially about a desirable BMI. Lower body mass may be associated with lower energy consumption and, consequently, nutrient intake below the physiological needs. However, there is also the assumption that a lower body mass is associated with a higher resting metabolic rate in patients with AD [52]. Therefore, this study indicated that a higher BMI can be protective against AD mortality which might be explained by a higher energy reserve. However further investigation on the individual level should explore how BMI mediates AD mortality.

The present study has limitations. The adopted ecological design uses as a sampling unit a group of individuals and non-individuals, and this can interfere with the results. However, the data analyzed here are representative of the population of the capitals and present essential data for future studies using different research designs. Another limitation is the method of estimating AD’s prevalence that used data on free dispensing of specific drugs for AD treatment by the public health system, which would limit the sample to only users of this system. However, we believe that this limitation does not reduce the importance of our findings since the system’s user population is quite large and representative.

In conclusion, this study found a low prevalence of AD among the Brazilian elderly (300 cases per 100,000 elderly). Furthermore, we found an AD’s mortality rate of 36 deaths per 100,00 elderlies. AD’s prevalence was positively associated with PHC coverage and negatively associated with ultra-processed foods consumption and PAL. AD’s mortality rate was inversely associated with the proportion of obese elderly and elderly living on up to half the minimum wage and positively associated with diabetes prevalence.


I am grateful for the collaboration of MPS, for data analysis and writing, GNN, for database suggestions, JSB, for the thorough review, and other authors for writing and final review.


  1. 1. WHO. Ageing and health [Internet]. 2021.
  2. 2. IBGE. INSTITUTO BRASILEIRO DE GEOGRAFIA E ESTATÍSTICA. Projeções e estimativas da população do Brasil e das unidades da federação. [Internet]. 2018.
  3. 3. Falco A de Cukierman DS, Hauser-Davis RA Rey NA. ALZHEIMER’S DISEASE: ETIOLOGICAL HYPOTHESES AND TREATMENT PERSPECTIVES. Química Nova [Internet]. 2015;39(1):63–80. Available from:
  4. 4. WHO. Dementia [Internet]. 2021.
  5. 5. Dias EG, de Andrade FB, Duarte YA de O, Santos JLF, Lebrão ML. Advanced activities of daily living and incidence of cognitive decline in the elderly: The SABE Study. Cadernos de Saúde Pública. 2015;31(8):1623–35. pmid:26375642
  6. 6. Cheng ST. Cognitive Reserve and the Prevention of Dementia: the Role of Physical and Cognitive Activities. Current Psychiatry Reports [Internet]. 2016;18(9). Available from: pmid:27481112
  7. 7. Verhaar BJH, de Leeuw FA, Doorduijn AS, Fieldhouse JLP, van de Rest O, Teunissen CE, et al. Nutritional status and structural brain changes in Alzheimer’s disease: The NUDAD project. Alzheimer’s and Dementia: Diagnosis, Assessment and Disease Monitoring. 2020;12(1):1–9. pmid:32793798
  8. 8. Chaves ML, Camozzato AL, Godinho C, Piazenski I KJ. Incidence of Mild Cognitive Impairment and Alzheimer Disease in Southern Brazil. Journal of Geriatric Psychiatry and Neurology [Internet]. 2009 Sep 23;22(3):181–7. Available from: pmid:19307320
  9. 9. Nitrini R, Caramelli P, Herrera E, Bahia VS, Caixeta LF, Radanovic M, et al. Incidence of dementia in a community-dwelling Brazilian population. Alzheimer Dis Assoc Disord [Internet]. 2004;18(4):241–6. Available from: pmid:15592138
  10. 10. HERRERA J. E, CARAMELLI P NR. Estudo epidemiológico populacional de demência na cidade de Catanduva—Estado de São Paulo—Brasil. Revista Psiquiatria Clínica,. 1998;25 (2):70–3.
  11. 11. Scazufca M, Menezes PR, Vallada HP, Crepaldi AL, Pastor-Valero M, Coutinho LMS, et al. High prevalence of dementia among older adults from poor socioeconomic backgrounds in São Paulo, Brazil. International Psychogeriatrics. 2008;20(2):394–405.
  12. 12. Yamada T, Kadekaru H, Matsumoto S, Inada H, Tanabe M, Moriguchi EH, et al. Prevalence of dementia in the older Japanese-Brazilian population. Psychiatry and Clinical Neurosciences. 2002;56(1):71–5. pmid:11929573
  13. 13. FIOCRUZ. Instituto de Informação e Comunicação Cientícia e Tecnológica em Saúde. Sistema de Indicadores de saúde e Acompanhamento de Políticas Públicas do Idoso (SISAP-Idoso) [Internet]. Rio de Janeiro; 2011.
  14. 14. Ministério da Saúde B. Portaria Conjunta No 13, de 28 de novembro de 2017. Aprova o Protocolo Clínico e Diretrizes Terapêuticas da Doença de Alzheimer [Internet]. Brasília; 2017.—COMPLETA.pdf
  15. 15. BRASIL. MINISTÉRIO DA SAÚDE. DATASUS. Mortalidade—desde 1996 pela CID-10 [Internet]. 2020.
  18. 18. INSTITUTO BRASILEIRO DE GEOGRAFIA E ESTATÍSTICA. Pesquisa de Orçamentos Familiares [Internet]. 2018.
  19. 19. BRASIL. Ministerio da Saúde. e-Gestor Atenção Básica [Internet]. 2020.
  20. 20. Cao Q, Tan CC, Xu W, Hu H, Cao XP, Dong Q, et al. The Prevalence of Dementia: A Systematic Review and Meta-Analysis. Zhu LQ, editor. Journal of Alzheimer’s Disease [Internet]. 2020 Feb 4;73(3):1157–66. Available from: pmid:31884487
  21. 21. Bartoloni L, Blatt G, Insua I, Furman M, González MA, Hermann B, et al. A population-based study ofcognitive impairment in sociallyvulnerable adults in Argentina: The matanza riachuelo study preliminary results. Dementia e Neuropsychologia. 2014;8(4):339–44.
  22. 22. Fuentes P, Albala C. Atualização em envelhecimento e demência no Chile. Dementia e Neuropsychologia. 2014;8(4):317–22.
  23. 23. Fuentes P, Albala C. An update on aging and dementia in Chile TT—Atualização em envelhecimento e demência no Chile. Dementia & Neuropsychologia [Internet]. 2014;8(4):317–22. Available from:
  24. 24. Prince Martin, Wimo Anders, Guerchet Dr Maëlenn, Gemma-Claire Ali YTW and M P. Global prevalence of dementia. Alzheimer’s Disease International. 2015;1(9503):2112–7.
  25. 25. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: A systematic review and metaanalysis. Alzheimer’s and Dementia [Internet]. 2013;9(1):63–75.e2. Available from: pmid:23305823
  26. 26. Niu H, Álvarez-Álvarez I, Guillén-Grima F, Aguinaga-Ontoso I. Prevalencia e incidencia de la enfermedad de Alzheimer en Europa: metaanálisis. Neurología [Internet]. 2017 Oct;32(8):523–32. Available from:
  27. 27. UK. Department of Health. Dementia—a state of the nation report on dementia care and support in England [Internet]. 2013.
  28. 28. Dias A, Patel V. Closing the treatment gap for dementia in India. Indian J Psychiatry [Internet]. 2009 Jan;51 Suppl 1:S93–7. Available from: pmid:21416026
  29. 29. Nakamura AE, Opaleye D, Tani G, Ferri CP. Dementia underdiagnosis in Brazil. The Lancet [Internet]. 2015 Jan;385(9966):418–9. Available from: pmid:25706975
  30. 30. Matsunaga S, Fujishiro H, Takechi H. Efficacy and Safety of Cholinesterase Inhibitors for Mild Cognitive Impairment:A Systematic Review and Meta-Analysis. Journal of Alzheimer’s Disease. 2019;71(2):513–23. pmid:31424411
  31. 31. Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet [Internet]. 2016 Oct;388(10053):1459–544. Available from: pmid:27733281
  32. 32. James BD, Leurgans SE, Hebert LE, James BD, Leurgans SE, Scherr PA. Contribution of Alzheimer disease to mortality in the United States. 2014;
  33. 33. Lopez OL, Kuller LH. Epidemiology of aging and associated cognitive disorders: Prevalence and incidence of Alzheimer’s disease and other dementias [Internet]. 1st ed. Vol. 167, Handbook of Clinical Neurology. Elsevier B.V.; 2019. 139–148 p. Available from:
  34. 34. 2020 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia [Internet]. 2020 Mar 10;16(3):391–460.
  35. 35. BRASIL. Ministério da Saúde. Departamento de atenção básica. Política Nacional de Atenção Básica. Brasília; 2012.
  36. 36. Luck T, Roehr S, Rodriguez FS, Schroeter ML, Witte AV, Hinz A, et al. Memory-related subjective cognitive symptoms in the adult population: Prevalence and associated factors—results of the LIFE-Adult-Study. BMC Psychology. 2018;6(1):1–15.
  37. 37. Feter N, Leite JS, Caputo EL, Cardoso RK, Rombaldi AJ. Who are the people with alzheimer’s disease in brazil? Findings from the brazilian longitudinal study of aging. Revista Brasileira de Epidemiologia. 2021;24(April). pmid:33886873
  38. 38. who. WHO GUIDELINES ON PHYSICAL ACTIVITY AND SEDENTARY BEHAVIOUR [Internet]. Geneva: World Health Organization; 2020.
  39. 39. Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer’s disease: An analysis of population-based data. The Lancet Neurology. 2014;13(8):788–94. pmid:25030513
  40. 40. Desai P, Evans D, Dhana K, Aggarwal NT, Wilson RS, McAninch E, et al. Longitudinal Association of Total Tau Concentrations and Physical Activity With Cognitive Decline in a Population Sample. JAMA Network Open. 2021;4(8):e2120398. pmid:34379124
  41. 41. Francis H, Stevenson R. The longer-term impacts of Western diet on human cognition and the brain. Appetite [Internet]. 2013 Apr;63:119–28. Available from: pmid:23291218
  42. 42. Bayer-Carter JL, Green PS, Montine TJ, VanFossen B, Baker LD, Watson GS, et al. Diet Intervention and Cerebrospinal Fluid Biomarkers in Amnestic Mild Cognitive Impairment. Archives of Neurology [Internet]. 2011 Jun 1;68(6). Available from: pmid:21670398
  43. 43. Solfrizzi V, Custodero C, Lozupone M, Imbimbo BP, Valiani V, Agosti P, et al. Relationships of Dietary Patterns, Foods, and Micro- and Macronutrients with Alzheimer’s Disease and Late-Life Cognitive Disorders: A Systematic Review. Journal of Alzheimer’s Disease. 2017;59(3):815–49. pmid:28697569
  44. 44. Bednarz K, Siuda J. Alzheimer’s Disease and Type 2 Diabetes Mellitus: similarities in pathomechanisms lead to therapeutic opportunities. Neurologia i Neurochirurgia Polska [Internet]. 2021 Aug 6;1–11. Available from:
  45. 45. Nguyen TT, Ta QTH, Nguyen TKO, Nguyen TTD, Giau V van. Type 3 diabetes and its role implications in alzheimer’s disease. International Journal of Molecular Sciences. 2020;21(9):1–16.
  46. 46. de Miguel-Yanes JM, Jiménez-García R, Hernández-Barrera V, Méndez-Bailón M, de Miguel-Díez J, Muñoz-Rivas N, et al. Hospital Admissions in People With Alzheimer’s Disease or Senile Dementia According to Type 2 Diabetes Status: An Observational 10-Year Study. Vol. 33, American Journal of Alzheimer’s Disease and other Dementias. 2018. p. 12–9. pmid:28945135
  47. 47. Chornenkyy Y, Wang WX, Wei A, Nelson PT. Alzheimer’s disease and type 2 diabetes mellitus are distinct diseases with potential overlapping metabolic dysfunction upstream of observed cognitive decline. Brain Pathology. 2019;29(1):3–17. pmid:30106209
  48. 48. Ho AJ, Raji CA, Becker JT, Lopez OL, Kuller LH, Hua X, et al. Obesity is linked with lower brain volume in 700 AD and MCI patients. Neurobiology of Aging [Internet]. 2010 Aug;31(8):1326–39. Available from: pmid:20570405
  49. 49. Ho AJ, Raji CA, Saharan P, DeGiorgio A, Madsen SK, Hibar DP, et al. Hippocampal volume is related to body mass index in Alzheimer’s disease. NeuroReport [Internet]. 2011 Jan 5;22(1):10–4. Available from: pmid:21539003
  50. 50. Burns JM, Johnson DK, Watts A, Swerdlow RH, Brooks WM. Reduced lean mass in early Alzheimer disease and its association with brain atrophy. Archives of Neurology. 2010;67(4):428–33. pmid:20385908
  51. 51. Cronk BB, Johnson DK, Burns JM. Body mass index and cognitive decline in mild cognitive impairment. Alzheimer Disease and Associated Disorders. 2010;24(2):126–30. pmid:19571736
  52. 52. Doorduijn AS, de Van Der Schueren MAE, van de Rest O, de Leeuw FA, Hendriksen HMA, Teunissen CE, et al. Energy intake and expenditure in patients with Alzheimer’s disease and mild cognitive impairment: The NUDAD project. Alzheimer’s Research and Therapy. 2020;12(1):1–8. pmid:32979927